Blitzer R D, Becker R E
Psychopharmacology (Berl). 1985;85(2):173-7. doi: 10.1007/BF00428409.
Using a two-lever operant task rats were trained to discriminate 40 mg/kg IP of bupropion from saline. Despite bupropion's established dopaminergic activity in vitro and in vivo, it was found that the bupropion cue was neither mimicked by the dopaminergic drugs L-DOPA and bromocriptine nor blocked by a variety of neuroleptics (haloperidol, thioridazine, and thiothixene). In addition, bupropion was active in attenuating the behavior-suppressing effects of haloperidol, unlike amphetamine and the atypical antidepressants, nomifensine and viloxazine. The bupropion cue was not mimicked or disrupted by adrenergic or serotonergic drugs, but it did generalize to some stimulants (amphetamine, cocaine and caffeine) as well as to nomifensine and viloxazine. The generalizations were blocked by neuroleptics. These data indicate that bupropion's cue properties may not be based on its ability to modulate dopaminergic receptor activity. The possible involvement of phenylethylamine in the bupropion cue is also discussed.
利用双杠杆操作性任务，训练大鼠区分腹腔注射40毫克/千克安非他酮与生理盐水。尽管安非他酮在体外和体内都具有既定的多巴胺能活性，但发现安非他酮线索既未被多巴胺能药物左旋多巴和溴隐亭模拟，也未被多种抗精神病药物（氟哌啶醇、硫利达嗪和替沃噻吨）阻断。此外，与苯丙胺以及非典型抗抑郁药诺米芬辛和维洛沙嗪不同，安非他酮在减轻氟哌啶醇的行为抑制作用方面具有活性。安非他酮线索未被肾上腺素能或5-羟色胺能药物模拟或破坏，但它确实能泛化到一些兴奋剂（苯丙胺、可卡因和咖啡因）以及诺米芬辛和维洛沙嗪。这些泛化被抗精神病药物阻断。这些数据表明，安非他酮的线索特性可能并非基于其调节多巴胺能受体活性的能力。文中还讨论了苯乙胺在安非他酮线索中的可能作用。
